Tissue necrosis after chemotherapy in osteosarcoma as the important prognostic factor

Saudi Medical Journal

Volumn 29, Issue 8, 2008, Pages 1124-1129

  Sami, Sam H ^a   Rafati, Ali H ^a   Hodjat, Parsa ^a  

^a IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOXORUBICIN; FOLINIC ACID; IFOSFAMIDE; METHOTREXATE;

ADOLESCENT; ADULT; ARTICLE; BONE RESECTION; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CANCER SURVIVOR; CONTROLLED STUDY; DRUG MEGADOSE; DRUG RESPONSE; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IRAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; OSTEOSARCOMA; POSTOPERATIVE PERIOD; PREDICTION; PREOPERATIVE PERIOD; PROGNOSIS; SCHOOL CHILD; SURVIVAL TIME; TUMOR NECROSIS; BONE TUMOR; CHILD; MIDDLE AGED; NECROSIS; PATHOLOGY; TREATMENT OUTCOME;

ADOLESCENT; ADULT; BONE NEOPLASMS; CHILD; FEMALE; HUMANS; MALE; MIDDLE AGED; NECROSIS; OSTEOSARCOMA; PROGNOSIS; TREATMENT OUTCOME;

EID: 56149099692     PISSN: 03795284     EISSN: 16583175     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Link MP, Goorin AM, Miser AW, Green AA, Pratt CB, Belasco JB, et al. The effect of adjuvant chemotherapy on relapse - free survival in patients with osteosarcoma of the extremity. N Engl J Med 1986; 314: 1600-1606.
2. Rosen G, Nirenberg A, Caparros B. Osteosarcoma: Eighty percent, three year, disease free survival with combination chemotherapy (T7). Natl Cancer Inst Monogr 1981; 56: 213-220.
3. Rosen G, Nirenberg A, Caparros B. Preoperative chemotherapy for osteogenic sarcoma: Selection of post operative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer 1982; 49: 1221-1238.
4. Winkler K, Beron G, Kotz R. Neoadjuvant chemotherapy for osteosarcoma: results of a cooperative German/Austrian study. J Clin Oncol 1984; 2: 617-623.
5. Krailo M, Ertle I, Makly J. A randomized study comparing high-dose methotrexate with moderate-dose methotrexate as components or adjuvant chemotherapy in childhood nonmetastatic osteosarcoma: A report from children's cancer study group. Med Pediatr Oncol 1987; 15: 69-77.
6. Goorin AM, Perez-Atayde A, Gebhardt M, Andersen JW, Wilkinson RH, Delorey MJ, et al. Weekly high dose methotrexate and doxorubicin for osteosarcoma: The Dana-Farber Cancer Institute/the Children's HSospital-study III. J Clin Oncol 1987; 5: 1178-1184.
7. Winkler K, Beron G, Delling G, Heise U, Kabisch H, Purfurst C, et al. Neoadjuvant chemotherapy for osteosarcoma results of a randomized cooperative trial (COSS-82) with salvage chemotherapy. J Clin Oncol 1988; 6: 329-337.
8. Bacci G, Picci P, Ruggieri P, Mercuri M, Avella M, Capanna R, et al. Primary chemotherapy and delayed surgery (neoadjuvant chemotherapy) for osteosarcoma of the extremities. The Instituto Rizzoli Experience in 127 patients treated preoperatively with intravenous methotrexate (high versus moderate doses) and intraarterial cisplatin. Cancer 1990; 65: 2539-2553.
9. French Bone Tumor Study Group. Age and dose of chemotherapy as major prognostic factor in trial of adjuvant: Therapy of osteosarcoma combining two alternating drug combinations and early prophylactic lung irradiation. Cancer 1988; 61: 1304-1311.
10. Meyers PA, Heller G, Healy J. Chemotherapy for nonmetastatic osteogenic sarcoma: The Memorial Sloan-Kettering experience. J Clin Oncol 1992; 10: 5-15.
11. Bramwell VH, Burgers M, Sneath R, Souhami R, van Oosterom AT, Votar PA et al. A comparison of two short intensive adjuvant chemotherapy regimens in operable osteosarcoma of limbs in children and young adults: the first study of European osteosarcoma intergroup. J Clin Oncol 1992; 10: 1579-1591.
12. Bacci G, Picci P, Ferrari S, Ruggieri P, Casadei R, Tienghi A, et al. Primary chemotherapy and delayed surgery for nonmetastatic osteosarcoma of the extremities: Results in 164 patients preoperatively treated with high doses of methotrexate followed by doxorubicin and cisplatin. Cancer 1993; 72: 3227-3228.
13. Provisor AJ, Ettinger LJ, Nachman JB, Krailo MD, Makley JT, Yunis, EJ, et al. Treatment of nonmetastatic osteosarcoma of the extremity with pre and postoperative chemotherapy: A report from children's cancer group. J Clin Oncol 1997; 15: 79-84.
14. Souhami RI. Craft AW, Van der Eijken JW, Nooij M, Spooner D, Bramwell. VH, et al. Randomized trial or two regimens of chemotherapy in operable osteosarcoma: A study of the European osteosarcoma intergroup, Lancet 1997; 350: 911-917.
15. Fuchs N, Bielack SS, Epler D, Bicling P, Delling G, Körholz D, et al, Longterm results of German-Autrian-Swiss osteosarcoma study group protocol COSS-86 or intensive multidrug chemotherapy and surgery for osteosarcoma of the limbs. Ann Oncol 1998; 9: 893-899.
16. Bielack S, Kempf B, Schwenzer D, Neoadjuvant therapy des lokali sierten osteosarkoms der extremetaten. Erfahrunger der cooperativen osteosarko mstudiengruppe coss an 925 patienern, Klin Padiatr 1999; 211, 260-270.
17. Huvos A. Osteosarcoma: Pathologic assessment of preoperative (neoadjuvant) chemotherapy. In bone tumors: Diagnosis, treatment, and prognosis. 2nd ed. Philadelphia (PA): W.B. Saunders; 1991. p. 122-128.
18. Rosen G, Caparrs B, Huvos A, Kosloff C, Nirenberg A, Cacavio A, et al. Preoperative chemotherapy for osteosarcoma: Selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer 1982; 49: 1221-1230.
19. Springfield D, Schakel M, Spanier S. Spontanous necrosis in osteosarcoma. Clin Orthop 1991; 263: 233-237.
20. Bacci G, Picci P, Pignatti G, De Cristofaro R, Dallari D, Avella M, et al. Neoadjuvant chemotherapy nonmetastatic osteosarcoma of the extremities. Clin Orthop 1991; 270: 87-98.
21. Meyers PA, Garlick R, Healy J, Intensification of preoperative chemotherapy for osteosarcoma: Results of memorial Sloan_Ketterling T12 protocol. J Clin Oncol 1998; 162: 2452-2458.
22. Picci P, Sangiorgi L, Rougraff B, Neff J. Relationship of chemotherapy-induced necrosis and surgical margins no local recurrence in osteosarcoma. J Clin Oncol 1994; 12: 2699-2705.
23. Arndr Ca, Crist WM, Common musculoskeletal tumors of childhood and adolescence. N Engl J Med 1999; 341: 342-352.
24. Hutchins LF, Unger JM, Crowley JJ. Underrepresentation of patients 65 years of age or older in cancer treatment trials. N Engl J Med 1999; 341: 2061-2067.
25. Davis AM, Bell RS, Goodwin PJ, Prognositic factors in osteosarcoma: A critical review. J Clin Oncol 1994; 12: 423-431.
26. Bieling P, Rehan N, Winkler P. Tumor size and prognosis in aggressively treated osteosarcoma, J Clin Oncol 1996; 14: 848-858.
27. Saeter G, Elomaa I, Wahlqvist Y, Alvegärd TA, Wiehe T. Monge O. et al. Prognostic factors in bone sarcomas. Acta Orthop Scand Suppl 1997; 273: 156-160.
28. Winkler K, Beron G, Schellong G, Cooperative osteosarkomstudie coss_77: Ergebnisse nach uber 4 Jahren. Klin Padiatr 1982; 194: 251-256.
29. Bacci G, Ferrari, Prognostic significance or serum alkaline phosphatase measurements in patients with osteosarcoma treated with adjuvant or neoadjuvant chemotherapy. Cancer 1993: 71: 1224-1230.
30. Bacci G, Ferrari, S. Prognostic significance of serum lactate dehydrogenase in patients with osteosarcoma of the extremities, J Chemother 1995; 6: 204-210.
31. Bacci G, Picci P, Ferrari S. Influence of adriamycin dose in the outcome of patients with osteosarcoma treated with multidrug neoadjuvant chemotherapy: Results of two sequential studies. J chemother 1993: 5: 237-246.
32. Benjamin RS, Patel SR, Armen T. The value of isofosfamide in postoperative neoadjuvant chemotherapy of osteosarcoma. Prac Am Soc Clin Oncol 1995; 14: 516.
33. Delepine N, Delepine G, Jasmin C, Desbois JC, Cornille H, Mathe G, Importance age and methotrexate dosage: Prognosis in children and young adults with high-grade osteosarcomas. Biomed Pharmacother 1988; 42: 257-262.
34. Provisor AJ, Ettinger LJ, Nachman JB. Treatment of nonmetastatic osteosarcoma of the extremity with pre and postoperative chemotherapy. A report from the children's cancer group. J Clin Oncol 1997; 15: 76-84.
35. Saeter G, Alvegrad TA, Elomaa I. Treatment of osteosarcoma of the extremities with the t-10 protocol, with emphasis of the effects of preoperative chemotheraphy with the single agent high dose methotrexate: A Scandivian Sarcoma Group Study. J Clin Oncol 1991; 9: 1766-1775.
36. Bacci G, Ferrari S, Delepine N. Predictive factors of the histologic response to primary chemotherapy in osteosarcoma of the extremity: Study of 272 patients preoperatively treated with high dose methotrexate doxorubicine and cisplatin. J Clin Oncol 1998; 16: 658-663.
37. Goldie JH. Coldman AJ. A mathematical model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 1979; 63: 1727-1733.